...CEO and a director; and Tamara Seymour as CFO; all of whom formerly served at Favrille Inc....

...Longenecker as president, CEO and a director. Longenecker is the former president and CEO of Favrille Inc....
...hired Richard Ghalie as CMO and Tamara Seymour as CFO, both of whom served at Favrille...

...the combined company, and Favrille will own 29%. The remaining 7% will be issued to Favrille's...
...common stock. The deal is expected to close by year end. After a June restructuring, Favrille's...
...Favrille said it would like to sell or license the antibodies (see BioCentury, June 2). Favrille Inc....

...Business: Cancer Hired: John Bender as SVP of R&D, formerly SVP of clinical research at Favrille...

...is expected to start Phase III testing this half to treat medullary thyroid cancer (MTC). Favrille...

...E2007) to treat Parkinson’s disease (PD) after the compound failed in a Phase III study Favrille...

...expects to reduce expenses by about $4M for 2008 and about $10M annually thereafter 5/29/08 Favrille...

...GBM) (see BioCentury, June 9 & April 21) . The worst micro-cap failure came for Favrille Inc....
...NASDAQ:AVAN), Needham, Mass. Biogen Idec Inc. (NASDAQ:BIIB), Cambridge, Mass. Elan Corp. plc (NYSE:ELN), Dublin, Ireland Favrille Inc....

...trial. Nevertheless, McCarthy said the high-risk program is a potential blockbuster. He expects data mid-year. Favrille...

...testing. On the week, Lexicon added $0.04 to $2.11. Fade to black Cancer vaccine company Favrille...
...cut 132 people (92%) to 12. The cuts include six of its eight executive officers. Favrille...
...cutaneous T cell lymphoma (CTCL), and an undisclosed preclinical candidate to treat multiple sclerosis (MS). Favrille...